Clinical Trials Logo

Filter by:
NCT ID: NCT01466868 Terminated - Clinical trials for Diffuse Large B Cell Lymphoma

Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

AKTIL
Start date: November 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the antitumor efficacy and the safety of MK 2206 in patients with relapsed or refractory diffuse large B cell lymphoma.

NCT ID: NCT01464476 Terminated - Clinical trials for Cardiovascular Diseases

Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)

SHIELD-2
Start date: November 2011
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of Azimilide on the incidence of cardiovascular hospitalizations, cardiovascular emergency department visits or cardiovascular death in patients with Implantable Cardioverter Defibrillators (ICDs)

NCT ID: NCT01458548 Terminated - Clinical trials for Post-transplantation Lymphoproliferative Disorder

Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)

Start date: December 2002
Phase: Phase 2
Study type: Interventional

Post-transplantation lymphoproliferative disorder (PTLD) develops in one to ten per cent of transplant recipients and can be EBV-associated. To improve long-term efficacy after rituximab monotherapy and to avoid the toxicity of CHOP seen in first-line treatment, the investigators initiated an international multicentre phase II trial to test whether the subsequent application of rituximab and four courses of three-weekly CHOP would improve the outcome of patients with PTLD: PTLD-1, sequential treatment (ST).

NCT ID: NCT01458119 Terminated - Fabry Disease Clinical Trials

Open-Label Phase 3 Long-Term Safety Study of Migalastat

AT1001-041
Start date: October 14, 2011
Phase: Phase 3
Study type: Interventional

This was a long-term, open-label study of migalastat (123 milligrams [mg] of migalastat [equivalent to 150 mg of migalastat hydrochloride]) (migalastat) in participants with Fabry disease who completed treatment in a previous monotherapy trial with migalastat.

NCT ID: NCT01455025 Terminated - Clinical trials for Acute Myeloid Leukemia

Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia

PRIMAL
Start date: January 2012
Phase: Phase 1
Study type: Interventional

This is a phase 1, dose escalation study of Plerixafor in combination with granulocyte-colony stimulating factor , Daunorubicin and Cytarabine in adults patients with relapsed acute myeloid leukemia .

NCT ID: NCT01452347 Terminated - Clinical trials for Heart Valve Diseases

Dabigatran Etexilate in Patients With Mechanical Heart Valves

RE-ALIGN
Start date: October 2011
Phase: Phase 2
Study type: Interventional

To validate the dosing algorithm for dabigatran etexilate in patients receiving a mechanical heart valve.

NCT ID: NCT01452100 Terminated - Clinical trials for Cholesterol Embolism Systemic

Efficacy of Prednisone in Patients With Severe Systemic Atheroembolism (Cholesterol Cristal Embolism)

MECCORT
Start date: June 2011
Phase: Phase 2
Study type: Interventional

Cholesterol cristal embolization (CCE) is an orphan multisystem vascular condition occurring in elderly with severe atherosclerosis. In most patients, avoiding the precipitating factors and combination of statin and RAS inhibitor are recommended. The lack of randomized controlled trial in CCE precludes significant advances. The investigators decided to assess whether prednisone started early, at mild dosage and for a short period prevents death and progression to end-stage renal failure in patients with severe CCE, as compared to placebo.

NCT ID: NCT01450878 Terminated - Ischemia Clinical Trials

Renal Graft Function After Treatment With Erythropoietin (EPO)

FRETEP
Start date: December 2011
Phase: Phase 3
Study type: Interventional

Background : Numerous studies have outlined the cellular pleiotropic effects of erythropoietin (EPO) and their role in the prevention of ischemic-reperfusion lesion such as after acute ischemic injury of the brain or the heart. However, most of these studies were carried out in animal models and no definitive proof exists today to demonstrate that EPO has similar beneficial effects in human pathology. Purpose : The aim of the study is to demonstrate that in humans, EPO can protect against ischemic-reperfusion lesions in a model of ischemia i.e. kidney transplantation.

NCT ID: NCT01449292 Terminated - Pulmonary Emphysema Clinical Trials

Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)

ASPIRE
Start date: June 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate the safety and efficacy of AeriSeal System treatment plus optimal medical therapy compared in patients with advanced upper lobe predominant (ULP) heterogeneous emphysema.

NCT ID: NCT01449175 Terminated - Emphysema Clinical Trials

A Registry Study of the AeriSeal® System or Lung Volume Reduction in Patients With Advanced Emphysema

Start date: January 2011
Phase: N/A
Study type: Observational

The purpose of this study is to provide post market clinical follow-up (PMCF) to obtain long term safety and efficacy information about the AeriSeal System treatment in patients with advanced emphysema.